# A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced Pancreatic Cancer

> **NCT05657418** · PHASE1 · TERMINATED · sponsor: **Shanghai Junshi Bioscience Co., Ltd.** · enrollment: 8 (actual)

## Conditions studied

- Advanced Pancreatic Cancer

## Interventions

- **DRUG:** JS107
- **COMBINATION_PRODUCT:** JS107 combination with Toripalimab

## Key facts

- **NCT ID:** NCT05657418
- **Lead sponsor:** Shanghai Junshi Bioscience Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-03-29
- **Primary completion:** 2025-01-04
- **Final completion:** 2025-01-04
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Company research and development strategy adjustment
- **Last updated:** 2025-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05657418

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05657418, "A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05657418. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*